Bempegaldesleukin

Phase 3Protein / enzyme

NNektar Therapeutics

Bempegaldesleukin is one of 165 biologic programs targeting Metastatic Melanoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

164

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic MelanomaActive, not recruiting

MelanomaActive, not recruiting

Bladder CancerActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

COVID-19Active, not recruiting

Metastatic MelanomaPhase 1

Active, not recruiting

MelanomaPhase 3

Active, not recruiting

Bladder CancerPhase 3

Active, not recruiting

Renal Cell CarcinomaPhase 3

Active, not recruiting

COVID-19Phase 1

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Bempegaldesleukin

NNektar Therapeutics

Phase 3

1 2

COVID-19 Vaccine

Moderna

Preclinical

27 3

Aldactone

Pfizer

Preclinical

1 4

Nexavar

Bayer

Preclinical

1 5

Rayaldee

OOrganon and Co

Preclinical

1 6

Benadryl

PParkedale

Preclinical

1 7

Nadroparin

GSK

Preclinical

1 8

Statins

Sanofi

Preclinical

1 9

Olokizumab

UCB

Preclinical

1 10

DAS181

AAnsun Biopharma, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Solid Tumor Malignancies1 trial

REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies

Terminated·NNektar Therapeutics·Phase 1/2·NCT03435640·64 enrolled

Bladder Cancer1 trial

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT04209114·114 enrolled

Renal Cell Carcinoma1 trial

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Terminated·NNektar Therapeutics·Phase 3·NCT03729245·623 enrolled

Safety and Efficacy1 trial

A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer

Completed·NNykode Therapeutics ASA·Phase 1/2·NCT03548467·41 enrolled

Pembrolizumab1 trial

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

Terminated·NNektar Therapeutics·Phase 2/3·NCT04969861·1 enrolled

5 more indications

COVID-191 trial

A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19

Completed·NNektar Therapeutics·Phase 1·NCT04646044·30 enrolled

Advanced or Metastatic Solid Tumors1 trial

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

Terminated· Pfizer logo

Pfizer·Phase 1/2·NCT04052204·3 enrolled

Metastatic Melanoma1 trial

A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab

Withdrawn·NNektar Therapeutics·Phase 1·NCT04955262

Melanoma1 trial

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

Terminated·NNektar Therapeutics·Phase 3·NCT04410445·765 enrolled

Metastatic Urothelial Cancer1 trial

A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer

Completed·NNektar Therapeutics·Phase 2·NCT03785925·192 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Bempegaldesleukin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bempegaldesleukin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bempegaldesleukin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nektar Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: NNektar Therapeutics

Bempegaldesleukin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Solid Tumor Malignancies1 trial

Bladder Cancer1 trial

Renal Cell Carcinoma1 trial

Safety and Efficacy1 trial

Pembrolizumab1 trial

COVID-191 trial

Advanced or Metastatic Solid Tumors1 trial

Metastatic Melanoma1 trial

Melanoma1 trial

Metastatic Urothelial Cancer1 trial

References

Drug Info

Quick Facts

Related News